Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-label, Single-arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Neonates With Repeated Electroencephalographic Seizures

X
Trial Profile

A Multicenter, Open-label, Single-arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Neonates With Repeated Electroencephalographic Seizures

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 18 Jan 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brivaracetam (Primary) ; Brivaracetam (Primary)
  • Indications Neonatal seizures
  • Focus Pharmacokinetics
  • Acronyms PETITE
  • Sponsors UCB Biopharma
  • Most Recent Events

    • 22 Jul 2022 This trial has been completed in Hungary (End Date: 29 May 2021) according to European Clinical Trials Database record.
    • 21 Feb 2022 Status changed to discontinued due to due to enrolment challenges.
    • 20 Jan 2022 This trial has been discontinued in Belgium (Date of the global end of the trial : 23-Dec-2021), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top